# Table of Contents

**Highlights of This Issue** 4497

**SPECIAL FEATURES**

**CCR 20th Anniversary Commentary**

4499  
**CCR 20th Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer**  
Mohammad Aminur Rahman and Dong M. Shin

**CCR Translations**

4502  
**Imaging Tumor Acidity: pH-Low Insertion Peptide Probe for Optoacoustic Tomography**  
Yana K. Reshetnyak  
See related article, p. 4576

4505  
**Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch**  
Tian Zhang and Andrew J. Armstrong  
See related article, p. 4619

**Molecular Pathways**

4508  
**Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling**  
Fabio Conforti, Yisong Wang, Jose A. Rodriguez, Anna Teresa Alberobello, Yu-Wen Zhang, and Giuseppe Giaccone

**Review**

4514  
**Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise**  
Jaegil Kim, Rehan Akbani, Chad J. Creighton, Seth P. Lerner, John N. Weinstein, Gad Getz, and David J. Kwiatkowski

**CCR Focus**

4526  
**On Innovating and Inspiring the Clinical Trial Enterprise**  
Susan E. Bates

4527  
**Advancing Clinical Trials to Streamline Drug Development**  
Susan E. Bates, Donald A. Berry, Sanjeeve Balasubramaniam, Stuart Bailey, Patricia M. LoRusso, and Eric H. Rubin

**CANCER THERAPY: CLINICAL**

4569  
**Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer**  

**PERSONALIZED MEDICINE AND IMAGING**

4576  
**Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo**  
Charles W. Kimbrough, Anil Khanal, Matthew Zeideman, Bigya R. Khanal, Neal C. Burton, Kelly M. McMasters, Selwyn M. Vickers, William E. Grizzle, and Lacey R. McNally  
See related commentary, p. 4502
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4597</td>
<td>Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies</td>
<td>Netanya I. Pollock, Lin Wang, Gerald Wallweber, William E. Gooding, Weidong Huang, Ahmed Chenna, John Winslow, Malabika Sen, Kala A. DeGrave, Hua Li, Yan Zeng, and Jennifer R. Grandis</td>
</tr>
<tr>
<td>4619</td>
<td>Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer</td>
<td>Di Cui, Jinli Dai, Jill M. Keller, Atsushi Mizokami, Shujie Xia, and Evan T. Keller See related commentary. p. 4505</td>
</tr>
<tr>
<td>4630</td>
<td>Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice</td>
<td>Sun-Jin Kim, Ho Jeong Lee, Mark Seungwook Kim, Hyun Jin Choi, Junqin He, Qiyu Wu, Kenneth Aldape, Jeffrey S. Weinberg, W.K. Alfred Yung, Charles A. Conrad, Robert R. Langley, François Lehembre, Utsi Regenass, and Isaiah J. Fidler</td>
</tr>
<tr>
<td>4642</td>
<td>Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo</td>
<td>Sarah E.M. Herman, Rashida Z. Mustafa, Jade Jones, Deanna H. Wong, Mohammed Farooqui, and Adrian Wiestner</td>
</tr>
<tr>
<td>4652</td>
<td>Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models</td>
<td>Yusuke Kobayashi, Hiroyasu Kashima, Ren-Chin Wu, Jin-Gyoung jung, Jun-Chun Huang, Jinghua Gu, Jianhua Xuan, Lori Sokoll, Kala Visvanathan, Le-Ming Shih, and Tian-Li Wang</td>
</tr>
<tr>
<td>4663</td>
<td>Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma</td>
<td>Jennifer E. Amengual, Paul Johannet, Maximilian Lombardo, Kelly Zullo, Daniela Hoehn, Govind Bhagat, Luigi Scotto, Xavier Jirau-Serrano, Dejan Radeski, Jennifer Heinen, Hongfeng Jiang, Serge Cremers, Yuan Zhang, Simon Jones, and Owen A. O’Connor</td>
</tr>
<tr>
<td>4676</td>
<td>Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK-Mediated Phosphorylation of Akt</td>
<td>Naitao Wang, Ming Yao, Jin Xu, Yizhou Quan, Kaising Zhang, Ru Yang, and Wei-Qiang Gao</td>
</tr>
<tr>
<td>4686</td>
<td>SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer</td>
<td>Carminia Maria Della Corte, Claudio Belleviscente, Giovanni Vidocimini, Donata Vitaliano, Umberto Malapelle, Marina Accardo, Alessio Fabozzi, Alfonso Fiorelli, Morena Fasano, Federica Papaccio, Erika Martineelli, Teresa Troiani, Giancarlo Tromone, Mario Santini, Roberto Bianco, Forunato Cardiello, and Floriana Morgillo</td>
</tr>
<tr>
<td>4698</td>
<td>SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer</td>
<td>XiaoTun Zhang, Ilsa M. Coleman, Lisha G. Brown, Lawrence D. True, Lori Kollath, Jared M. Lucas, Hung-Ming Lam, Ruth Dempit, Eva Corey, Lindy Chery, Bryce Lakeby, Celestia S. Higano, Bruce Montgomery, Martine Roudier, Paul H. Lange, Peter S. Nelson, Robert L. Vessella, and Colm Morrissey</td>
</tr>
</tbody>
</table>
Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer

Keap1–Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein
Ming-Hsien Chien, Wei-Jiunn Lee, Feng-Koo Hsieh, Chia-Feng Li, Tsu-Yao Cheng, Ming-Yang Wang, Jin-Shing Chen, Iyh-Ming Chow, Yi-Hua Jan, Michael Hsiao, Kuo-Tai Hua, and Min-Liang Kuo

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children’s Oncology Group

LETTER TO THE EDITOR
Siltuximab for Multicentric Castleman Disease—Letter
Raphael Teipel, Rainer Ordemann, Ulrike Proske, Frank Dietrich, Marika Mende, Gerhard Ehninger, Frank Kroschinsky, and Uwe Platzbecker

ABOUT THE COVER
This is a section of human LN-229 glioblastoma growing in the brain of nude mice. Immunohistochemical staining shows heterogeneous expression of endothelin receptors ET_1R depicted in green and ET_2R depicted in red. For details see the article by Kim and colleagues on page 4630 of this issue.
## Clinical Cancer Research

21 (20)

*Clin Cancer Res* 2015;21:00-4740.

### Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/21/20

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>